GlaxoSmithKline's malaria vaccine, Mosquirix, got an EMA green light just last month, but it doesn't mean efforts to develop additional vaccines have halted. PATH's Malaria Vaccine Initiative (MVI) is teaming up with protein manufacturer CMC Biologics to develop monoclonal antibodies that could inform future development of MVI's malaria candidates.
With a brand-new $156 million Gates Foundation grant in hand, the PATH Malaria Vaccine Initiative has signed on Switzerland-based Mymetics to develop and produce virosome-based vaccine formulations for a malaria transmission-blocking vaccine candidate.
Malaria and the mosquitoes that carry it may soon have more to contend with than mosquito nets and insecticides, thanks to the PATH Malaria Vaccine Initiative and a $156 million grant from the Bill & Melinda Gates Foundation. The award was announced Sunday by Bill Gates, co-chair of the Foundation, in a speech at the American Society of Tropical Medicine and Hygiene's annual meeting.
PATH, Inovio zero in on DNA malaria vaccine
Expanding an already solid partnership, PATH Malaria Vaccine Initiative and Inovio Pharmaceuticals will work together to advance malaria vaccine development and new vaccination delivery technologies.
A GlaxoSmithKline malaria vaccine posted surprisingly lackluster results in a Phase III trial, putting a damper on solid results from previous studies. The vaccine against the mosquito-borne illness proved only 30% effective when given to African children in a clinical trial.
PATH Malaria Vaccine Initiative created a new central reference lab to standardize the ability to measure performance of various malaria vaccine formulations.
In a late-stage trial of 6,000 children, three doses of GlaxoSmithKline's malaria vaccine RTS,S (also known as Mosquirix) cut the risk of children contracting malaria in a follow-up conducted
J&J;, GSK team on malaria vaccine
The PATH Malaria Vaccine Initiative (MVI) is collaborating with GlaxoSmithKline and Johnson & Johnson's vaccine unit Crucell to test second-generation version of GSK's experimental malaria
The GAVI Alliance has committed $100 million to support a meningitis A vaccine called MenAfriVac developed by Seattle-based PATH. The vaccine, which was developed with the help of a $70 million
The PATH Malaria Vaccine Initiative (MVI) will have use of Liquidia Technologies' PRINT particle technology for its research into new, more effective malaria vaccines. The technology helps